المساهمون: Zhen Zhang, Study Principal Investigator

المصدر: A Prospective Randomized Phase II Trial of CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for Microsatellite Stable Locally Advanced Rectal Cancer (TORCH-iTNT)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06281405Test

المؤلفون: Inner Mongolia Cancer Hospital Affiliated To Inner Mongolia Medical University, Shanxi Province Cancer Hospital

المساهمون: Ji Dongmei, Associated Professor

المصدر: A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06195228Test

المساهمون: Zhiguo Luo, MD, PhD, Professor and Chief Surgeon

المصدر: Single-arm II Phase Study of Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06041724Test

المساهمون: Zhimin Shao, Director of General Surgery of Fudan Shanghai Cancer Center

المصدر: Study of Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- (Open, Randomized, Phase II )

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05949541Test

المساهمون: Jian Zhang,MD, MD, Ph.D

المصدر: A Phase 1 Study to Evaluate the Efficacy and Safety of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05942378Test

المساهمون: Ji Dongmei, Associate Professor

المصدر: A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05924256Test

المساهمون: Jialei Wang, professor of medicine

المصدر: Moroto Y, Kha T, KotanS Takayama K, Mazda O. terferon-beta snal may up-regulate PD-L1 expressn through F9-dependent and dependent pathways lung cancer cells. Bchem Bphys Res Commun. 2018 Dec 9;507(1-4):330-336. do 10.1016/j.bbrc.2018.11.035. Epub 2018 Nov 14.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I; WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015 Sep;10(9):1243-1260. doi: 10.1097/JTO.0000000000000630.
Boyero L, Sanchez-Gastaldo A, Alonso M, Noguera-Ucles JF, Molina-Pinelo S, Bernabe-Caro R. Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy. Cancers (Basel). 2020 Dec 11;12(12):3729. doi: 10.3390/cancers12123729.
Herbst RS, Garon EB, Kim DW, Cho BC, Gervais R, Perez-Gracia JL, Han JY, Majem M, Forster MD, Monnet I, Novello S, Gubens MA, Boyer M, Su WC, Samkari A, Jensen EH, Kobie J, Piperdi B, Baas P. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. J Thorac Oncol. 2021 Oct;16(10):1718-1732. doi: 10.1016/j.jtho.2021.05.001. Epub 2021 May 26.
Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. Cells. 2020 Feb 27;9(3):561. doi: 10.3390/cells9030561.
Cabrita R, Mitra S, Sanna A, Ekedahl H, Lovgren K, Olsson H, Ingvar C, Isaksson K, Lauss M, Carneiro A, Jonsson G. The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. Cancers (Basel). 2020 Mar 21;12(3):742. doi: 10.3390/cancers12030742.
Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology. 2013 Oct 1;2(10):e27025. doi: 10.4161/onci.27025.
The Study of Envafolimab Plus Docetaxel in Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC Previously Treated With a PD-1 Inhibitor Combined With Chemotherapy

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05910034Test

المساهمون: Peng Wang, Clinical Professor

المصدر: A Phase II Study to Evaluate the Efficacy and Safety of Cryoablation Combined With Sintilimab Plus Lenvatinib as First-line Treatment in Patients With Unresectable Advanced Intrahepatic Cholangiocarcinoma (ICC)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05835245Test

المساهمون: Peng Wang, Clinical Professor

المصدر: A Phase II Study of Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05823987Test

المساهمون: Zhimin Shao, Professor

المصدر: Phase II Clinical Study of Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Prior Adjuvant Therapy With CDK4/6 Inhibitors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05806047Test